Methadone in the treatment of neuropathic pain

Pain Research and Management

Volumn 8, Issue 3, 2003, Pages 149-154

  Gagnon, Bruno ^a   Almahrezi, Abdulaziz ^b   Schreier, Gil ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer pain; Methadone; Neurophathic pain; Opioids

Indexed keywords

ANILERIDINE; CODEINE; FENTANYL; HYDROMORPHONE; LAXATIVE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ALLODYNIA; ARTICLE; CANCER; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL ASSESSMENT; NAUSEA; NEUROPATHIC PAIN; PROSPECTIVE STUDY; SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 0344468131     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/236718     Document Type: Article

References (65)

1. Classification of Chronic Pain. Mersky H, Bogduk N, eds. Seattle: IASP Press, 1994.
2. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400.
3. Bennett GF. Neuropathic pain. In: Textbook of Pain. Wall PD, Melzack R, eds. New York: Churchill Livingstone, 1994.
4. Bennett GJ. Animal models of neuropathic pain. In: Progress in Pain Research Management. Gebhart GB, Hammond DL, Jensen TS, eds. Seattle: IASP Publications, 1994:495-510.
5. Smith TE, Chong MS. Neuropathic pain. Hosp Med 2000;61:760-6.
6. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991;47:644-66.
7. Zech DFJ, Grond S, Lynch J, et al. Validation of World Health Organization guidelines for cancer pain relief - A 10-year prospective-study. Pain 1995;63:65-76.
8. Moulin DE. Neuropathic cancer pain: Syndromes and clinical controversies. In: Topics in Palliative Care. Bruera E, Portenoy RK, eds. New York: Oxford University Press, 1998:7-29.
9. Jensen TS, Gottrup H, Sindrup SH, et al. The clinical picture of neuropathic pain. Eur J Pharmacol 2001;429:1-11.
10. Besson JM. The neurobiology of pain. Lancet 1999;353:1610-5.
11. Bridges D, Thompson SWN, Rice ASC. Mechanism in neuropathic pain. Br J Anaesth 2001;87:12-26.
12. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959-64.
13. Bennett GJ. Update on the neurophysiology of pain transmission and modulation: Focus on the NMDA-receptor. J Pain Symptom Manage 2000;19:S2-S6.
14. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neuro 1991;41:1024-8.
15. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753-8.
16. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain - A randomized trial in postherpetic neuralgia. Neuro 1998;50:1837-41.
17. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
18. McQuay HJ, Jadad AR, Carroll D, et al. Opioid sensitivity of chronic pain: A patient-controlled analgesia method. Anaesthesia 1992;47:757-67.
19. Davis MP, Walsh D. Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
20. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997;223:5-8.
21. Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-70.
22. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8.
23. Davar G, Hama A, Deykin A, et al. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 1991;553:327-30.
24. Yamamoto T, Yaksh TL. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 1992;49:121-8.
25. Tal M, Bennett GJ. Neuropathic pain sensations are differentially sensitive to dextrorphan. Neuroreport 1994;5:1438-40.
26. Eide PK, Jorum E, Stubhaug A, et al. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain 1994;58:347-54.
27. Persson J, Axelsson G, Hallin RG, et al. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 1995;60:217-22.
28. Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neuro 1997;48:1212-8.
29. Morley J, Makin M. The use of methadone in cancer pain poorly responsive to opioids. Pain Rev 1998;5:51-8.
30. Manfredi PL, Borsook D, Chandler SW, et al. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain 1997;70:99-101.
31. Scholes CF, Gonty N, Trotman IF. Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care (Engl) 1999;8:26-9.
32. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995;62:259-74.
33. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-20.
34. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharma 1987;26:1235-8.
35. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-9.
36. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: Implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-9.
37. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci 1994;15:190-7.
38. Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride. Pain 1996;64:283-91.
39. Yaksh TL. Preclinical models of nociception. In: Anesthesia: Biological Foundations. Yaksh TL, Lynch C, Zapol WM, Biebuyck JF, Saidman LJ, eds. Philadelphia: Lippincott-Raven, 1997:685-718.
40. Jadad AR, Carroll D, Glynn CJ, et al. Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992;339:1367-71.
41. McQuay HJ, Bullingham RE, Moore RA. Acute opiate tolerance in man. Life Sci 1981;28:2513-7.
42. Dole VP, Kreek MJ. Methadone plasma level: Sustained by a reservoir of drug in tissue. Proc Natl Acad Sci USA 1973;70:10.
43. Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986;11:87-106.
44. Ventafridda V, Ripamonti C, Bianchi M, et al. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986;1:203-7.
45. Galer BS, Coyle N, Pasternak GW, et al. Individual variability in the response to different opioids: Report of five cases. Pain 1992;49:87-91.
46. MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: The application of alternate opioid therapy. Pain 1993;53:353-5.
47. Bruera E, Watanabe S, Fainsinger RL, et al. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995;62:141-6.
48. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-15.
49. De Conno F, Groff L, Brunelli C, et al. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14:2836-42.
50. Lawlor PG, Turner KS, Hanson J, et al. Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer 1998;82:1167-73.
51. Agency for Health Care Policy Research. Management in Cancer Pain: Clinical Practice Guideline. Rockville, MD, N. 9-0592: AHCPR, 1994.
52. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. Ann Oncol 1998;9:79-83.
53. Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain. Pain 2002;96:325-8.
54. Mercadante S, Casuccio A, Agnello A, et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998;16:3656-61.
55. Procter MJ, Headley PM. Comparison of NMDA receptor involvement in the anti-nociceptive effects of methadone, morphine and fentanyl in anaesthetised rats. In: Abstracts: 9th World Congress on Pain, Seattle, WA: IASP Press, 1999:535.
56. Shimoyama N, Shimoyama M, Elliott KJ, et al. d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 1997;283:648-52.
57. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999;18:120-5.
58. Jadad AR. Opioids in the treatment of neuropathic pain: A systematic review of controlled clinical trials. In: Topics in Palliative Care. Bruera E, Portenoy RK, eds. New York: Oxford University Press, 1998:31-40.
59. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003;60:927-34.
60. Shir Y, Rosen G, Zeldin A, et al. Methadone is safe for treating hospitalized patients with severe pain. Can J Anaesth 2001;48:1109-13.
61. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999;17:3307-12.
62. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001;19:2898-904.
63. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4.
64. Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer 2002;10:523-8.
65. Bruera E. Autonomic failure in patients with advanced cancer. J Pain Symptom Manage 1989;4:163-6.